<DOC>
	<DOC>NCT02487030</DOC>
	<brief_summary>This study will evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) with or without ribavirin (RBV) in Egyptian adults with chronic genotype 4 hepatitis C virus (HCV) infection.</brief_summary>
	<brief_title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
	<criteria>Key Willing and able to provide written informed consent. Chronic HCV infection (≥ 6 months) documented by medical history or liver biopsy HCV genotype 4 at screening HCV treatment naive or prior participation in this study or study GSUS3340138 (Cohorts 1 and 2 only) Cohort 3 only: HCV treatmentexperienced (previously received therapy for HCV infection with an interferon (IFN)containing regimen, with or without RBV and/or an HCV NS3/NS4A protease inhibitor (PI) Body mass index (BMI) ≥ 18 kg/m^2 Screening laboratory values within defined thresholds Use of effective protocolapproved contraception methods Key History of clinicallysignificant illness or any other major medical disorder that may interfere with treatment, assessment or compliance with the protocol Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) Pregnant or nursing females or male with pregnant female partner Clinicallyrelevant drug or alcohol abuse within 12 months of screening Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HCV genotype 4 (GT-4)</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>GS-7977</keyword>
	<keyword>GS-5885</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>ledipasvir</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C, Chronic</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>